Weight Loss With Exenatide Treatment

NCT01590433 on ClinicalTrials.gov · last registry update 2021-06-23

An unusually large phase 4: 249 participants, more than double the 75 typical for the stage. The sponsor logged completion for January 2019. Primary outcome, as filed: Change in Body Weight. exenatide is approved in the US, but not for obesity — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: Jody Dushay
Sponsor type: Other
Enrollment: 249
Started: 2012-03
Primary completion: 2019-01 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Body Weight

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.